Aldeyra Therapeutics Sees Unusually Large Options Volume (NASDAQ:ALDX)

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) saw some unusual options trading on Tuesday. Investors purchased 31,566 put options on the stock. This is an increase of 1,329% compared to the average volume of 2,209 put options.

Aldeyra Therapeutics Trading Down 70.7%

Shares of NASDAQ:ALDX opened at $1.24 on Wednesday. The firm has a 50 day simple moving average of $4.92 and a 200-day simple moving average of $5.08. Aldeyra Therapeutics has a twelve month low of $1.07 and a twelve month high of $6.87. The company has a market capitalization of $74.62 million, a PE ratio of -2.18 and a beta of 0.97.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its earnings results on Friday, February 27th. The biotechnology company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03. As a group, equities research analysts predict that Aldeyra Therapeutics will post -0.92 EPS for the current fiscal year.

Institutional Trading of Aldeyra Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. 683 Capital Management LLC increased its position in Aldeyra Therapeutics by 126.9% during the second quarter. 683 Capital Management LLC now owns 1,080,000 shares of the biotechnology company’s stock worth $4,136,000 after buying an additional 604,000 shares during the period. Los Angeles Capital Management LLC purchased a new stake in Aldeyra Therapeutics in the second quarter valued at approximately $63,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Aldeyra Therapeutics in the third quarter valued at approximately $721,000. SG Americas Securities LLC acquired a new stake in shares of Aldeyra Therapeutics in the fourth quarter valued at approximately $62,000. Finally, Inspirion Wealth Advisors LLC purchased a new position in shares of Aldeyra Therapeutics during the fourth quarter worth approximately $52,000. Institutional investors and hedge funds own 59.71% of the company’s stock.

More Aldeyra Therapeutics News

Here are the key news stories impacting Aldeyra Therapeutics this week:

• Neutral Sentiment: Short‑interest reporting in feeds today appears inconsistent/unreliable (data shows zeros/NaN), so it’s not a clear signal on its own — monitor official exchange filings for confirmation.
• Negative Sentiment: FDA declined to approve reproxalap, issuing a Complete Response Letter that blocks the drug’s U.S. approval and undermines Aldeyra’s commercial pathway. This is the primary driver of the stock collapse. US FDA declines to approve Aldeyra’s drug for eye disorder
• Negative Sentiment: Company confirmed receipt of a Complete Response Letter for the reproxalap NDA; the corporate release formalizes the regulatory setback and increases uncertainty about future timelines and funding needs. Aldeyra Therapeutics Receives Complete Response Letter
• Negative Sentiment: Multiple news outlets report this is a repeat rejection (third time reported), amplifying investor concern that the program may not reach approval without substantial additional data or resubmission. FDA rejects Aldeyra’s dry eye drug for third time
• Negative Sentiment: Large spike in bearish options — traders bought ~31,566 put contracts today (a >1,000% jump vs typical put volume), signaling aggressive downside positioning and likely adding to selling pressure.
• Negative Sentiment: Several law firms (Block & Leviton, Johnson Fistel and others) have launched investigations or solicited shareholders about potential securities claims, increasing legal risk and investor concern about management/disclosures. Block & Leviton investigation alert Johnson Fistel solicitation
• Negative Sentiment: News coverage and commentary (MSN, Seeking Alpha) emphasize the rejection and market reaction, which can reinforce negative sentiment and further pressure the share price. Aldeyra plunges as FDA rejects dry eye disease therapy

Wall Street Analysts Forecast Growth

Separately, BTIG Research reissued a “buy” rating on shares of Aldeyra Therapeutics in a report on Tuesday. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $9.50.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.